UiPath Inc vs Rocket Lab USA Inc — how do they compare? UiPath Inc trades at $13.56 (market cap $6.91B), while Rocket Lab USA Inc trades at $67.48 (market cap $43.74B). The key difference: Rocket Lab USA Inc is far larger — about 6.3× UiPath Inc's market cap, and UiPath Inc is trading nearer its 52-week high, Rocket Lab USA Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold UiPath Inc for 139 Days and Rocket Lab USA Inc for 29 Days on average.
| PATH | RKLB | |
|---|---|---|
Market Cap | $6.91B | $43.74B |
Volume | 34,321,250 | 22,892,581 |
Sector | Technology | Industrials |
52-Week High | $19.29 | $150.23 |
52-Week Low | $9.38 | $39.48 |
Typical Hold Time | 139 Days | 29 Days |
Enterprise Value | $5.70B | $41.57B |
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) trades at $13.07, down 0.23% with bearish technical signals despite strong fundamentals. The company shows improving financials with revenue growth from $1.43B in 2025 to projected $1.7B in 2026, transitioning to profitability with a 21.03% net margin. Recent partnerships with Snowflake and BDO highlight strategic positioning in AI automation, though technical indicators show resistance at $13 with RSI suggesting mixed momentum.
PATH offers compelling value with a P/E of 19.78 and analyst consensus target of $15.13 (16% upside), but faces execution risks and competitive pressure. The stock's bearish technical setup contrasts with fundamental improvement, creating potential for volatility. Investors should weigh strong profitability metrics against recent price weakness and mixed analyst sentiment.
Rocket Lab (RKLB) trades at $71.92, down 4.18% today, with neutral technical signals and strong analyst support. The company recently secured its largest commercial Electron deal - 20 launches with Synspective - boosting its backlog past 100 missions. Despite negative profitability metrics, revenue growth continues with 2026 projections showing improvement from 2025's $602 million. The stock trades at elevated valuation multiples with P/S of 51.96 and P/B of 12.52.
RKLB presents a growth story with significant contract wins and expanding launch capacity, though profitability remains elusive. The 76% analyst buy rating and $107 consensus target suggest substantial upside potential. Key risks include intense SpaceX competition, high cash burn, and valuation concerns. Investors must weigh growth trajectory against persistent losses and competitive pressures in the evolving space industry.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →